The FDA has approved dostarlimab-gxly (Jemperli®, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for patients with mismatch repair–deficient (dMMR) or microsatellite instability­–high (MSI-H) endometrial cancer, as determined by an FDA-approved test. Background: "Dostarlimab is an immune checkpoint inhibitor that targets the programmed cell death 1 (PD-1) receptor," wrote Mansoor R. Mirza, MD, Chief Oncologist at Copenhagen University Hospital in Denmark,...

The FDA has approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for treatment of mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen or who are not eligible for curative surgery or radiation. Diagnosis is determined by an FDA-approved test. "Endometrial cancer is the most common gynecologic malignancy in the developed world and has the highest rate of dMMR/microsatellite instability–high (MSI-H) s...

To continue our mission to deliver up-to-date, clinically relevant content from the health care community, we have created NEW Oncology Data Advisor Data Hubs. Each Data Hub is categorized by tumor type to make it easy for all members of the oncology team to find the most up-to-date information from across the health care landscape. View the Data Hubs below now!